Manitoba
Health

Provincial Programs and Services
300 Carlton, Winnipeg MB R3B 3M9
www.manitoba.ca

Bulletin #63

Changes to Pharmacare and Employment & Income Assistance Drug Programs benefit coverage for Oxycontin (oxycodone CR) effective March 26, 2010

Currently Oxycontin (oxycodone CR) 5, 10, 20, 40 and 80 mg tablets are eligible benefits under the Pharmacare and Employment & Income Assistance Drug Programs. Effective **March 26, 2010**, Oxycontin will move from Part 1 benefit status to Part 3 Exception Drug Status for Pharmacare and Employment & Income Assistance Drug Plans. This change will help to ensure benefit coverage for these drugs is only targeted to those patients who meet the established criteria recommended by an expert committee of physicians and pharmacists. In doing so, Pharmacare and Employment & Income Assistance Drug Programs will provide benefit coverage which is similar to that provided by most other provincial and territorial drug plans.

New patients starting Oxycontin therapy on or after March 26, 2010

Effective **March 26, 2010,** Pharmacare and Employment & Income Assistance Drug Programs will require physicians to apply for Part 3 Exception Drug Status (EDS) coverage for all **new patients** starting Oxycontin therapy. Patients will be required to meet the following criteria before they will be considered for benefit coverage for Oxycontin.

1. Diagnosis of cancer related pain; PLUS
   Patients who are unable to tolerate or receive an adequate response to either the regular release dosage forms of oxycodone or the sustained release preparations of morphine or hydromorphone; OR
2. Pain management in a specified chronic pain diagnosis (details regarding patient's condition and previous medication history are required); PLUS
   Patients who are unable to tolerate or receive an adequate response to either the regular release dosage forms of oxycodone or the sustained release preparations of morphine or hydromorphone.

Patients currently on Oxycontin therapy prior to March 26, 2010

Patients who have been on existing Oxycontin therapy prior to March 26, 2010 will be provided benefit coverage until **May 26, 2010.** Effective May 26, 2010, Pharmacare and Employment & Income Assistance Drug Programs will require Part 3 Exception Drug Status (EDS) be in place for a patient's Oxycontin therapy if they wish to have continued benefit coverage for this medication. The period between March 26, 2010 and May 26, 2010 will allow patients time to contact their physicians to apply on their behalf.

BULLETIN # 63

Manitoba Drug Benefits and Interchangeability Formulary Amendments

The following amendments will take effect on March 26, 2010.

The amended Manitoba Specified Drug Regulation and Drug Interchangeability Formulary Regulation will be available on the Manitoba Health website *http://www.gov.mb.ca/health/mdbif* on the effective date of March 26, 2010.

Bulletin 63 is currently available for download:

http://www.gov.mb.ca/health/mdbif/bulletin63.pdf

Inside This Issue	
Part 1 Deletions	Page 1
Part 3 Additions	Page 1
Category Deletions	Page 1-2
Interchangeable Product Price Changes	Page 2

Part 1 Deletions

02319977 02319985 02319993	**pms-Oxycodone**	oxycondone	5 mg 10 mg 20 mg	Tablets	PMS
02258129 02202441 02202468 02202476 02202484	**Oxycontin**	oxycondone	5 mg 10 mg 20 mg 40 mg 80 mg	Controlled Released Tablets	PFR

Part 3 Additions

02319977 02319985 02319993	**pms-Oxycodone**	oxycondone	5 mg 10 mg 20 mg	Tablets	PMS

For patients who have tried and failed combination products (Percodan, Percocet, etc.) and have maximized the acetaminophen dose or have contraindications to acetaminophen.

02258129 02202441 02202468 02202476 02202484	**Oxycontin**	oxycondone	5 mg 10 mg 20 mg 40 mg 80 mg	Controlled Released Tablets	PFR

For the diagnosis of:
1. Cancer related pain; PLUS
Patients who are unable to tolerate or receive an adequate response to either the regular release dosage forms of oxycodone or the sustained release preparations of morphine or hydromorphone; OR
2. Pain management in a specified chronic pain diagnosis (details regarding patient's condition and previous medication history are required); PLUS
Patients who are unable to tolerate or receive an adequate response to either the regular release dosage forms of oxycodone or the sustained release preparations of morphine or hydromorphone.

Category Deletions

- Amoxicillin/Clavulanic Acid - 250 mg/125 mg - Tablets
- Desipramine HCl - 10 mg - Tablets
- Desipramine HCl - 75 mg - Tablets
- Fluoxetine - 20 mg/5 mL - Syrup
- Hydralazine - 25 mg - Tablets
- Ibuprofen - 600 mg - Tablets
- Mefenamic Acid - 250 mg - Capsules

- Methotrimeprazine - 5 mg - Tablets
- Methotrimeprazine - 25 mg - Tablets
- Methotrimeprazine - 50 mg - Tablets
- Orciprenaline - 2 mg/mL - Syrup

Interchangeable Product Price Changes

The following changes in prices have occurred: **($)**

00335053	Apo-Amitriptyline	amitriptyline	10 mg	Tablet	0.0664
00335061	Apo-Amitriptyline	amitriptyline	25 mg	Tablet	0.1211
00335088	Apo-Amitriptyline	amitriptyline	75 mg	Tablet	0.2347
02290332	Apo-Benazepril	benazepril	5 mg	Tablet	0.5577
02290340	Apo-Benazepril	benazepril	10 mg	Tablet	0.6595
02273918	Apo-Benazepril	benazepril	20 mg	Tablet	0.7567
00682039	Apo-Cal	calcium carbonate	500 mg	Tablet	0.041
02216256	Apo-Desipramine	desipramine	10 mg	Tablet	0.3804
02216264	Apo-Desipramine	desipramine	20 mg	Tablet	0.6704
00545031	Apo-Ferrous Gluconate	ferrous gluconate	300 mg	Tablet	0.0404
02246691	Apo-Hydroxyquine	hydroxychloroquine	200 mg	Tablet	0.4420
02284294	Apo-Oxcarbazepine	oxcarbazepine	150 mg	Tablet	0.6209
02284308	Apo-Oxcarbazepine	oxcarbazepine	300 mg	Tablet	1.2414
02284316	Apo-Oxcarbazepine	oxcarbazepine	600 mg	Tablet	2.4826
00312770	Apo-Prednisone	prednisone	5 mg	Tablet	0.0401
00550957	Apo-Prednisone	prednisone	50 mg	Tablet	0.1735